3rd Quarter - Report

WILLIAMS AND JENSEN, PLLC for GENENTECH INC

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

R&D Tax Credit Extension; TARP; H.R. 1429.

LobbyistCovered position, as disclosed
DAVID E FRANASIAK —
JACK STEVEN HART —
CHRISTOPHER W HATCHER —

Contacted: HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Food & Drug Administration (FDA); SENATE; White House Office; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1429 (110th)

Budget/Appropriations BUD

H.R. 2638 (Consoldidated Security, Disaster Assistance and Continuing Appropriations Act); Comparative Effectiveness legislation.

LobbyistCovered position, as disclosed
JACK STEVEN HART —
KARINA LYNCH —
GEORGE OLSEN —

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; White House Office; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 2638 (110th)

Copyright/Patent/Trademark CPT

Intellectual property issues; H.R. 5629 (Pathways to Biosimilars Act).

LobbyistCovered position, as disclosed
JACK STEVEN HART —
KARINA LYNCH —
GEORGE OLSEN —

Contacted: SENATE; Executive Office of the President (EOP); Food & Drug Administration (FDA); White House Office; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 5629 (110th)

Health Issues HCR

H.R. 6331/ S. 3101 (Medicare Improvements for Patients and Providers Act); H.R. 5629 (Pathway for Biosimilars Act); FDA Reform; Medicare Drug Benefit

LobbyistCovered position, as disclosed
JACK STEVEN HART —
KARINA LYNCH —
GEORGE OLSEN —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA)

Bills named: H.R. 5629 (110th), S. 3101 (110th), H.R. 6331 (110th)

Medicare/Medicaid MMM

H.R. 1424 (Emergency Economic Stabilization Act); S. 2029 (Physician Payments Sunshine Act); H.R. 6331/S. 3101 (Medicare Improvenents for Patients and Providers Act); Comparative Effectiveness Legislation.

LobbyistCovered position, as disclosed
JACK STEVEN HART —
CHRISTOPHER W HATCHER —
KARINA LYNCH —
GEORGE OLSEN —

Contacted: Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS); White House Office; Executive Office of the President (EOP); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1424 (110th), H.R. 6331 (110th), S. 3101 (110th), S. 2029 (110th)

Pharmacy PHA

H.R. 1038/S.623 (Access to Life-Saving Medicine Act, follow-on biologics); H.R. 1956 (Patient Protection and Innovative Biologic Medicines Act, follow-on biologics); H.R. 5629 (Pathway for Biosimilars Act); H.R. 5839 (Safeguarding America's Pharmaceuticals Act); S.1505 (Affordable Biologics for Consumers Act, follow-on biologics); S. 1695 (Biologics Price Competition and Innovation Act-follow-on biologics); S.2029 (Physician Payments Sunshine Act); S.596 (Safe Internet Pharmacy Act, clinical trials/drug safety)

LobbyistCovered position, as disclosed
JACK STEVEN HART —
KARINA LYNCH —
GEORGE OLSEN —

Contacted: White House Office; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 596 (110th), H.R. 5629 (110th), S. 2029 (110th), S. 1505 (110th), H.R. 1038 (110th), S. 623 (110th), H.R. 5839 (110th), H.R. 1956 (110th), S. 1695 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.